



MIRTLE MEDICAL INSTRUMENTAL IN WORLD'S FIRST VENTRICULAR ICMR PROCEDURE

April 15, 2025 – North Andover, Massachusetts – MiRTLE Medical LLC, a medical device company focused on patient monitoring and safety during an MRI, today announced that the Company's MRI Compatible 12-Lead ECG System was selected by the Team at Amsterdam University Medical Center (AUMC) to successfully treat a ventricular tachycardia patient in the world's first interventional MRI ablation.

"MiRTLE is the only MRI-safe 12-lead ECG device on the market. Regulatory cleared for clinical use in Europe, MiRTLE delivers the accurate ECG signals required by electrophysiologists to identify, map, and verify the heart's electrical activity, all requirements needed to treat complex arrhythmias while inside an MRI," stated Jay Ward, Executive Vice President at MiRTLE Medical.

"During ablation, MRI-images provide a better view of the anatomy of the heart and the instruments used for treatment, but also of the changes made to the treated cardiac tissue. Unlike X-ray images, the entire area surrounding the heart can be seen, including the blood vessels and valves. And the MRI offers the opportunity during the procedure to visualize the effects of the treatment on the myocardial tissue," stated Dr. Marco Götte, imaging cardiologist at Amsterdam UMC, initiator and project leader of the cardiac intervention MRI research program.

The innovative use of MRI in cardiac interventions has long been a focus for Amsterdam UMC's Heart Center. A key challenge here is that much medical equipment normally used for interventions is not suitable for use in an MRI environment. To make these materials MRI-compatible, Amsterdam UMC has been working with industrial partners Siemens Healthineers, Imricor and MiRTLE Medical for some time. "Normally the equipment and material that we use for ablations is made of metal, but an MRI scanner is in fact a huge, very strong magnet. So, we had to reinvent everything, from the catheters used to monitors and communication systems, to an MRI-compatible ECG system. With this step, we have firmly reaffirmed our role as a pioneer," stated Dr. Götte

Mr. Ward further stated "by providing the ECG signals needed by electrophysiologists, MiRTLE is instrumental in treating complex ventricular arrhythmias under real-time MRI guidance. These MRI interventional procedures have the potential to deliver significant improvement in the acute and long-term success rates for patients, while shifting away from the harmful X-ray exposure to patients and providers. Congratulations to the talented team at AUMC in achieving this milestone."



About MiRTLE Medical LLC

MiRTLE Medical is a privately funded medical device company founded in 2012. MiRTLE Medical designs and manufactures MRI-compatible 12-lead ECG monitors and software to enable cardiac monitoring inside an MRI to expand clinical and operational procedures to improve patient outcomes.

The AUMC Press Release may be found here: <https://amsterdamumc.org/en/spotlight/global-first-mri-used-in-treatment-of-complex-cardiac-arrhythmia.htm>

For more information, please visit www.mirtlemed.com or contact:

Jay Ward
Executive Vice President
Jay.ward@mirtlemed.com
978.918.7223 x113